OGM Evaluated as a Method for Investigating Abnormal NIPT Results due to its Ability to Detect Chromosomal Structural Variations Found in Recurrent Pregnancy Loss
October 14 2022 - 8:00AM
Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the
publication of a peer-reviewed study evaluating optical genome
mapping (OGM) as a method for investigating abnormal noninvasive
prenatal testing (NIPT) results because of its ability to
accurately identify complex structural aberrations relevant to
recurrent pregnancy loss and infertility.
In a case study from Hangzhou Maternity and Child Care Hospital,
researchers analyzed samples from a pregnant subject who had an
abnormal NIPT result in her second pregnancy, after experiencing a
spontaneous abortion the prior year. The study sought to determine
OGM’s utility for detection of chromosome breakages and fusions
found in complex chromosomal rearrangements (CCR), which can
significantly increase an abnormal pregnancy outcome for carrier
couples. The study reports that about 70% of CCR carriers are
phenotypically normal, but they have a high risk of recurrent
miscarriage, subfertility or infertility, and pregnancy
abnormalities due to conceiving offspring with unbalanced CCRs.
The researchers used OGM as part of a confirmatory workflow
after amniocentesis, karyotyping (KT), and chromosomal microarray
analysis (CMA) identified suspected structural rearrangements with
unknown origins, believed to indicate a CCR event. The study
reported that OGM revealed complex structural aberrations that KT
and CMA did not identify, confirming the subject as a carrier of a
CCR involving three chromosomes and four breakpoints, and thereby
aiding researchers in subsequent prenatal diagnosis and genetic
counseling.
Erik Holmlin, PhD, president and chief executive officer of
Bionano commented, “We are pleased to see the study provide
validation of OGM’s potential utility for prenatal analysis and
show how OGM may help researchers understand the underlying genetic
etiology of recurrent miscarriage or pregnancy abnormalities. We
believe OGM could be used as a comprehensive follow-up genome
analysis in cases with a positive NIPT screen or for some high-risk
pregnancies.”
This publication can be found here:
https://molecularcytogenetics.biomedcentral.com/articles/10.1186/s13039-022-00619-9
About Bionano Genomics
Bionano Genomics is a provider of genome analysis solutions that
can enable researchers and clinicians to reveal answers to
challenging questions in biology and medicine. The Company’s
mission is to transform the way the world sees the genome through
OGM solutions, diagnostic services and software. The Company offers
OGM solutions for applications across basic, translational and
clinical research. Through its Lineagen, Inc. d/b/a Bionano
Laboratories business, the Company also provides diagnostic testing
for patients with clinical presentations consistent with autism
spectrum disorder and other neurodevelopmental disabilities.
Through its BioDiscovery business, the Company also offers an
industry-leading, platform-agnostic software solution, which
integrates next-generation sequencing and microarray data designed
to provide analysis, visualization, interpretation and reporting of
copy number variants, single-nucleotide variants and absence of
heterozygosity across the genome in one consolidated view. For more
information, visit www.bionanogenomics.com,
www.bionanolaboratories.com or www.biodiscovery.com
Forward-Looking Statements of Bionano
Genomics
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “believe,” “can,” “may,” “potential” and
similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) convey
uncertainty of future events or outcomes and are intended to
identify these forward-looking statements. Forward-looking
statements include statements regarding our intentions, beliefs,
projections, outlook, analyses or current expectations concerning,
among other things, the ability of OGM to detect chromosome
breakages and fusions found in CCRs, the utility of OGM for
prenatal analysis. Each of these forward-looking statements
involves risks and uncertainties. Actual results or developments
may differ materially from those projected or implied in these
forward-looking statements. Factors that may cause such a
difference include the risks and uncertainties associated with: the
impact of the COVID-19 pandemic on our business and the global
economy; general market conditions; changes in the competitive
landscape and the introduction of competitive technologies or
improvements to existing technologies; failure of future study
results to support those demonstrated in the paper referenced in
this press release; failure OGM to detect CCRs; failure of OGM to
detect genomic structural variations in a prenatal analysis;
changes in our strategic and commercial plans; our ability to
obtain sufficient financing to fund our strategic plans and
commercialization efforts; the ability of medical and research
institutions to obtain funding to support adoption or continued use
of our technologies; and the risks and uncertainties associated
with our business and financial condition in general, including the
risks and uncertainties described in our filings with the
Securities and Exchange Commission, including, without limitation,
our Annual Report on Form 10-K for the year ended December 31, 2021
and in other filings subsequently made by us with the Securities
and Exchange Commission. All forward-looking statements contained
in this press release speak only as of the date on which they were
made and are based on management’s assumptions and estimates as of
such date. We do not undertake any obligation to publicly update
any forward-looking statements, whether as a result of the receipt
of new information, the occurrence of future events or
otherwise.
CONTACTSCompany Contact:Erik
Holmlin, CEOBionano Genomics, Inc.+1 (858)
888-7610eholmlin@bionanogenomics.com
Investor Relations:Amy ConradJuniper Point+1
(858) 366-3243amy@juniper-point.com
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Apr 2023 to Apr 2024